GlaxoSmithKline to transfer rights to Iodex and Ostocalcium for Rs 16.5bn
GlaxoSmithKline Pharmaceuticals Limited said that it will transfer its rights pertaining to the Iodex pain relief and Ostocalcium brands to GlaxoSmithKline Asia Private Limited for INR 1,649 crores. The deal, which will be subject to approval from shareholders, regulatory approvals, and customary closing conditions, is expected to be closed by the end of the year. […]